Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS

Background: A sensitive liquid chromatography coupled with tandem mass spectrometry (MS/MS) method for the analysis in a small volume of plasma of 14 tyrosine kinase inhibitors currently used (imatinib, dasatinib, ibrutinib, ponatinib, trametinib, sunitinib, cobimetinib, dabrafenib, erlotinib, lapatinib, nilotinib, bosutinib, sorafenib, and vemurafenib) has been developed and validated. This multianalyte liquid chromatography coupled with MS/MS assay is of interest for anticancer drug combination therapy. Methods: After a simple protein precipitation of plasma samples, the chromatographic separation was performed using an ultra performance liquid chromatography system coupled with MS/MS in a positive ionization mode. The mobile phase consisted of a gradient elution of 10 mmol/L formate ammonium buffer containing 0.1% (vol/vol) formic acid (phase A) and acetonitrile with 0.1% (vol/vol) formic acid (phase B) at a flow rate of 300 &mgr;L/min. Results: The analysis time was 5.0 minutes per run, and all analytes and internal standard eluted within 1.45–1.79 minutes. The calibration curves were linear over the range from 1 to 500 ng/mL for bosutinib, cobimetinib, dasatinib, ibrutinib, and trametinib, from 5 to 500 ng/mL for ponatinib and sunitinib; from 50 to 2500 ng/mL for lapatinib; from 750 to 100,000 ng/mL for vemurafenib, and from 10 to 2500 ng/mL for dabrafenib, erlotinib, imatinib, nilotinib, and sorafenib, with coefficients of correlation above 0.99 for all analytes. The intra- and interday imprecisions were below 14.36%. Conclusions: This method was successfully applied to therapeutic drug monitoring in clinical practice.

[1]  D. Ouellet,et al.  Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. , 2014, British journal of clinical pharmacology.

[2]  K. Flaherty,et al.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[3]  Jeffrey W. Clark,et al.  Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. , 2007, The oncologist.

[4]  D. Dorer,et al.  Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects , 2014, Cancer Chemotherapy and Pharmacology.

[5]  Wenping Ding,et al.  Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials , 2014, OncoTargets and therapy.

[6]  M. Molimard,et al.  Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[7]  A. Hulin,et al.  Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[8]  Vinod P. Shah,et al.  Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.

[9]  W. Figg,et al.  Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. , 2008, Journal of pharmaceutical and biomedical analysis.

[10]  T. Brümmendorf,et al.  Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. , 2012, Blood.

[11]  Peng Sun,et al.  Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma , 2015, Melanoma research.

[12]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[13]  S. Agrawal,et al.  Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia , 2009, International journal of hematology.

[14]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[15]  E. Rowinsky,et al.  A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer , 2008, Clinical Cancer Research.

[16]  D. Gustafson,et al.  Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues. , 2005, Journal of pharmaceutical and biomedical analysis.

[17]  I. Flinn,et al.  Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. , 2011, The Lancet. Oncology.

[18]  H. Burris,et al.  Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. , 2004, The oncologist.

[19]  Matthew Wongchenko,et al.  Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. , 2016, The Lancet. Oncology.

[20]  A. Paci,et al.  Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies. , 2014, European journal of cancer.

[21]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[22]  A. Joe,et al.  A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAFV600E mutation-positive metastatic melanoma , 2013, Cancer Chemotherapy and Pharmacology.

[23]  K. Zaman,et al.  Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[24]  J. Schellens,et al.  Moving towards dose individualization of tyrosine kinase inhibitors. , 2011, Cancer treatment reviews.

[25]  H. Kantarjian,et al.  Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. , 2015, The Lancet. Haematology.

[26]  R. Larson,et al.  Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  H. Gelderblom,et al.  Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[28]  J. Waddell,et al.  Drug Monographs: Dabrafenib and Trametinib , 2013, Hospital pharmacy.

[29]  P. Rutkowski,et al.  Trametinib: a MEK inhibitor for management of metastatic melanoma , 2015, OncoTargets and therapy.

[30]  F. Marincola,et al.  What’s new in melanoma? Combination! , 2015, Journal of Translational Medicine.

[31]  A. Racine‐Poon,et al.  Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  E. Choo,et al.  Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects. , 2013, Molecular pharmaceutics.

[33]  P. Hsyu,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib , 2016, Clinical Pharmacokinetics.

[34]  P. Queirolo,et al.  Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. , 2015, Cancer treatment reviews.

[35]  R. Roskoski Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. , 2016, Pharmacological research.

[36]  J. Byrd,et al.  The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia , 2015, Cancer Chemotherapy and Pharmacology.

[37]  E. Angelucci,et al.  Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders , 2015, Expert opinion on pharmacotherapy.

[38]  R. Govindan,et al.  Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). , 2014, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  M. Michaelson,et al.  Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study , 2013, British Journal of Cancer.

[40]  G. Cabibbo,et al.  Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice , 2015, Digestive Diseases.

[41]  Jianxiang Wang,et al.  Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. , 2009, Clinical therapeutics.

[42]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[43]  Y. Ohe,et al.  Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer , 2015, Cancer Chemotherapy and Pharmacology.

[44]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[45]  L. Couchman,et al.  An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography–tandem mass spectrometry , 2012, Analytical and Bioanalytical Chemistry.

[46]  J. Comeau,et al.  Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2013, The Annals of pharmacotherapy.

[47]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[48]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  T. Wilt,et al.  Targeted therapy for advanced renal cell carcinoma. , 2008, The Cochrane database of systematic reviews.

[50]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[51]  H. Renz,et al.  Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[52]  D. Schadendorf,et al.  Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. , 2015, European journal of cancer.

[53]  E. Song,et al.  Pharmacokinetic Properties of Two Erlotinib 150 mg Formulations with a Genetic Effect Evaluation in Healthy Korean Subjects , 2014, Clinical Drug Investigation.

[54]  J. Schellens,et al.  Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[55]  M. Egorin,et al.  A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[56]  C. Stewart,et al.  Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.